Evaluation of Immunological Changes and Clinical Efficacy of Specific Immunotherapy With Der p House Dust Mite Allergen in Polysensitized and Monosensitized Patients With Allergic Rhinitis and/or Asthma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Asthma; Perennial allergic rhinitis
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 01 Mar 2013 Biomarkers information updated
- 28 Feb 2013 New trial record